BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/18/2021 6:37:38 AM | Browse: 341 | Download: 527
 |
Received |
|
2021-03-22 21:44 |
|
Peer-Review Started |
|
2021-03-21 15:32 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-05-13 02:59 |
|
Revised |
|
2021-05-25 05:48 |
|
Second Decision |
|
2021-07-21 03:30 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-07-21 08:11 |
|
Articles in Press |
|
2021-07-21 08:11 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2021-09-13 00:59 |
|
Publish the Manuscript Online |
|
2021-09-18 06:37 |
| ISSN |
1949-8462 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Cardiac & Cardiovascular Systems |
| Manuscript Type |
Minireviews |
| Article Title |
Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Ahmed Abdalwahab, Ayman Al-atta, Azfar Zaman and Mohammad Alkhalil |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mohammad Alkhalil, DPhil, MRCP, Doctor, Doctor, Cardiothoracic Centre, Freeman Hospital, Freeman Road, Newcastle upon Tyne NE7 7DN, United Kingdom. mak-83@hotmail.com |
| Key Words |
Intensive lipid-lowering; Proprotein convertase subtilisin kexin 9 inhibitors; Ezetimibe; Plaque imaging; Low-density lipoprotein cholesterol |
| Core Tip |
Intensive lipid-lowering therapies using ezetimibe and more recently proprotein convertase subtilisin kexin 9 inhibitors have improved clinical outcomes. Unselective application of these treatments is undesirable and unaffordable and, therefore, has been guided by low-density lipoprotein cholesterol level. Nonetheless, the residual risk in the post-statin era is markedly heterogeneous. Emerging data show that intensive lipid-lowering therapy produce larger absolute risk reduction in patients with polyvascular disease, post coronary artery bypass graft and diabetes. Notably, these clinical entities share similar phenotype of large burden of atherosclerotic plaques. Novel plaque imaging may aid decision making by identifying patients with propensity to develop lipid rich plagues at multi-vascular sites. Those patients may be suitable candidates for intensive lipid lowering treatment. |
| Publish Date |
2021-09-18 06:37 |
| Citation |
Abdalwahab A, Al-atta A, Zaman A, Alkhalil M. Intensive lipid-lowering therapy, time to think beyond low-density lipoprotein cholesterol. World J Cardiol 2021; 13(9): 472-482 |
| URL |
https://www.wjgnet.com/1949-8462/full/v13/i9/472.htm |
| DOI |
https://dx.doi.org/10.4330/wjc.v13.i9.472 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
